8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 13, 2026·SEC
Material company update
Feb 11, 2026·SEC
Veru Inc.(VERU)Earnings, Financials & Key Ratios
VERU•NASDAQ
$3.12
Price updated Jun 30, 2026
AboutVeru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Show more
- Revenue$0-100.0%
- EBITDA-$25M+32.9%
- Net Income-$23M+39.9%
- EPS (Diluted)-1.07+61.8%
- ROE-89.74%+38.3%
VERU Price & Volume
Veru Inc. (VERU) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Cessation Drives Structural Liquidity Risk
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion risk
Key Thesis Takeaways
- Veru Inc.
- faces a precarious outlook characterized by a complete cessation of commercial revenue and a persistent reliance on external capital to fund its clinical development pipeline.
- The company's inability to generate top-line growth, coupled with a deep accumulated deficit of $325.4 million, suggests that the current business model remains fundamentally unsustainable without further dilutive financing.
- Investors should monitor the company's ability to manage its $8.3 million in total liabilities against a rapidly depleting cash position of $27.6 million as of 2026Q2.
Verdict Logic
the company's total lack of revenue and consistent quarterly cash outflows of $8.9 million in 2026Q2 present an imminent risk of liquidity exhaustion that outweighs potential clinical upside.
VERU Growth Metrics
Veru Inc. (VERU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM61.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM63.42%
Return on Capital
10 Years-47.46%
5 Years-71.66%
3 Years-102.36%
Last Year-70.11%
VERU Recent Earnings
Veru Inc. (VERU) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.13+54.4%
$0.28
Rev
—
$2M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$0.26+44.7%
$0.47
Rev
—
$2M
Q4 2025
Dec 17, 2025Metric
Actual
Est
EPS
$0.60-64.4%
$0.36
Rev
$247,064
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.50+9.1%
$0.55
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.13vs $0.28+54.4% | —vs $2M |
| Q1 2026 | Feb 11, 2026 | $0.26vs $0.47+44.7% | —vs $2M |
| Q4 2025 | Dec 17, 2025 | $0.60vs $0.36-64.4% | $247,064 |
| Q3 2025 | Aug 12, 2025 | $0.50vs $0.55+9.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Veru Inc. (VERU)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.12 | $50.08M | -2.92 | -100% | — | -89.74% | — | |
| $37.44 | $2.49B | -9.60 | -78.63% | -34596.22% | -50.72% | — | |
| $123.51 | $9.09B | -21.11 | — | — | -42.78% | — | |
| $3.15 | $131.17M | -926.47 | 10.37% | 52.16% | — | — | |
| $0.95 | $599.8K | -0.20 | -67.7% | -1319.55% | -105.46% | — | |
| $55.72 | $8.53B | 20.12 | 87.32% | 65.95% | 87.36% | — |
Compare VERU vs Peers
Veru Inc. (VERU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VERU SEC Filings & Documents
Veru Inc. (VERU) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VERU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VERU Frequently Asked Questions
Veru Inc. (VERU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Veru Inc. growing?
Veru Inc. (VERU) saw revenue decline by 100.0% over the past year.
Is VERU profitable?
Veru Inc. (VERU) reported a net loss of $14.1M for fiscal year 2025.
Dividend & Returns
What is VERU's return on equity?
Veru Inc. (VERU) has a return on equity (ROE) of -89.7%. Negative ROE indicates the company is unprofitable.
What is Veru Inc.'s free cash flow?
Veru Inc. (VERU) had negative free cash flow of $26.1M in fiscal year 2025, likely due to heavy capital investments.